NCT02919332

Delayed 18F-FDG PET/CT in Improving Visualization of Brain Tumors in Patients With Glioblastoma

Improved Visualization of Glioblastoma Using Delayed 18F-FDG PET/CT.

• Status: Withdrawn
• Phase: —
• Study type: Observational
• Enrollment: 0 (actual)
• Sponsor: Jonsson Comprehensive Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

This clinical trial studies how well delayed fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET)/computed tomography (CT) works in improving visualization of brain tumors in patients with glioblastoma. Radiotracers such as 18F-FDG are highly taken up by tumors in the brain and are visualized using PET/CT. Increasing the interval of time between 18F-FDG administration and PET/CT scan may improve the visualization of brain tumors in patients with glioblastoma.

Detailed description

PRIMARY OBJECTIVES: I. To improve the visualization/delineation of glioblastoma lesions using delayed 18F-FDG PET/CT imaging. OUTLINE: Patients receive fludeoxyglucose F-18 intravenously (IV). Patients then undergo a standard of care PET/CT scan at 60 minutes and a second PET/CT scan at 240 minutes after injection. Note: Standard Uptake Value (SUV) is defined for state-of-the art PET/CT scanners as Standardized uptake values = count activity per ml within region of interest (MBq/ml)/\[injected dose (MBq)/body weight (kgx1000)\]

Conditions

• Glioblastoma
• Glioma

Interventions

Type	Name	Description
PROCEDURE	Computed Tomography	Undergo 18F-FDG PET/CT
RADIATION	Fludeoxyglucose F-18	Given IV
PROCEDURE	Positron Emission Tomography	Undergo 18F-FDG PET/CT

Timeline

• Start date: 2016-06-08
• Primary completion: 2018-12-12
• Completion: 2018-12-12
• First posted: 2016-09-29
• Last updated: 2020-07-24

Locations

1 site across 1 country: United States